Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.82 |
| ▸ | PDE4A | P27815 | 5/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisdionin B SCHEMBL29896692 | 0.92 | ADORA2B (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL516018 | 0.91 | PDE4A (0.78) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL316911 | 0.90 | PDE4A (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL266179 | 0.89 | PDE4A (0.72) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Bisdionin C SCHEMBL10018600 | 0.89 | CHIT1 (0.75) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL516446 | 0.89 | ADORA2A (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Bisdionin D SCHEMBL16120988 | 0.89 | ADORA2B (0.79) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL23144749 | 0.88 | PDE4A (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| Pentifylline SCHEMBL147256 | 0.88 | PDE4A (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27334771 | 0.88 | PDE4A (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2011-07-14 | — | — | US | claimed |
| EP-2338481-A2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | Metaproteomics, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| US-7914831-B2 | Alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids from hops; nontoxic | METAPROTEOMICS, LLC (US) | 2011-03-29 | — | — | US | claimed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | claimed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | claimed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | claimed |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20250320430-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-10-16 | — | — | US | disclosed |
| WO-2025134877-A1 | KIT AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2025-06-26 | — | — | WO | disclosed |
| US-20250129308-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-04-24 | — | — | US | disclosed |
| CN-119404296-A | Semiconductor processing liquid, method for processing object to be processed, and method for manufacturing electronic device | 富士胶片株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20250017209-A1 | COMPOSITION, MANUFACTURING METHOD FOR SEMICONDUCTOR ELEMENT, AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE | FUJIFILM CORPORATION (JP) | 2025-01-16 | — | — | US | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | disclosed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | disclosed |
| US-20050096282-A1 | Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases | FLORIDA RESEARCH FOUNDATION, UNIVERSITY OF | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885ADORA2A 608/4885PDE4A 772/4885 |
| US-20260117148-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | TPMT, P2RY13, TST | ADORA2B 689/4885ADORA2A 559/4885PDE4A 3690/4885 |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885ADORA2A 608/4885PDE4A 772/4885 |
| US-20250017209-A1 | COMPOSITION, MANUFACTURING METHOD FOR SEMICONDUCTOR ELEMENT, AND CLEANING METHOD FOR SEMICONDUCTOR SUBSTRATE | SPOUT1, SRM, SMOX | ADORA2B 3037/4885ADORA2A 2668/4885PDE4A 1888/4885 |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | ADORA2B 1339/4885ADORA2A 608/4885PDE4A 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.